Focused On-demand Library for Transcription factor GATA-5

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We employ our advanced, specialised process to create targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q9BWX5

UPID:

GATA5_HUMAN

Alternative names:

GATA-binding factor 5

Alternative UPACC:

Q9BWX5; D9ZGF7; Q17RE2; Q86VU4

Background:

Transcription factor GATA-5, also known as GATA-binding factor 5, plays a pivotal role in cardiovascular development. It is essential for the transcriptional programs that drive smooth muscle cell diversity and is known to bind to the CEF-1 nuclear protein binding site in the cardiac-specific slow/cardiac troponin C transcriptional enhancer. This protein's involvement in the intricate processes of heart development underscores its significance in cardiovascular biology.

Therapeutic significance:

GATA-5 is linked to Congenital heart defects, multiple types, 5 (CHTD5), a disorder characterized by a spectrum of congenital heart abnormalities. The disease's association with variants affecting the GATA-5 gene highlights its potential as a target for therapeutic intervention. Understanding the role of Transcription factor GATA-5 could open doors to potential therapeutic strategies, offering hope for individuals affected by congenital heart defects.